Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2004 2
2005 3
2006 3
2007 1
2008 2
2009 1
2010 1
2012 2
2013 4
2015 2
2016 3
2017 1
2018 3
2019 2
2020 4
2021 4
2022 2
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
PARP inhibition in treatment of pancreatic cancer.
Hammel P, Zhang C, Matile J, Colle E, Hadj-Naceur I, Gagaille MP, Bouattour M, Cros J, de Mestier L, Lamuraglia M. Hammel P, et al. Among authors: lamuraglia m. Expert Rev Anticancer Ther. 2020 Nov;20(11):939-945. doi: 10.1080/14737140.2020.1820330. Epub 2020 Sep 16. Expert Rev Anticancer Ther. 2020. PMID: 32936674 Review.
Non-Invasive Ultrasonic Description of Tumor Evolution.
Griffon J, Buffello D, Giron A, Bridal SL, Lamuraglia M. Griffon J, et al. Among authors: lamuraglia m. Cancers (Basel). 2021 Sep 11;13(18):4560. doi: 10.3390/cancers13184560. Cancers (Basel). 2021. PMID: 34572788 Free PMC article.
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Among authors: lamuraglia m. Nat Commun. 2024 Mar 5;15(1):1985. doi: 10.1038/s41467-024-45974-w. Nat Commun. 2024. PMID: 38443333 Free PMC article. Clinical Trial.
Beneath HMGA2 alterations in pleomorphic adenomas: Pathological, immunohistochemical, and molecular insights.
Alsugair Z, Lépine C, Descotes F, Lanic MD, Pissaloux D, Tirode F, Lopez J, Céruse P, Philouze P, Fieux M, Wassef M, Baglin AC, Mihaela O, Castain C, Sudaka A, Uro-Coste E, Champagnac A, Costes-Martineau V, Laé M, Benzerdjeb N; REFCOR network*. Alsugair Z, et al. Hum Pathol. 2024 Oct;152:105633. doi: 10.1016/j.humpath.2024.105633. Epub 2024 Jul 30. Hum Pathol. 2024. PMID: 39089476 Free article.
Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1::PLAG1 Gene Fusion.
Alsugair Z, Perrot J, Descotes F, Lopez J, Champagnac A, Pissaloux D, Castain C, Onea M, Céruse P, Philouze P, Lépine C, Lanic MD, Laé M, Costes-Martineau V, Benzerdjeb N; and REFCOR Members. Alsugair Z, et al. Am J Surg Pathol. 2024 May 1;48(5):551-561. doi: 10.1097/PAS.0000000000002206. Epub 2024 Mar 18. Am J Surg Pathol. 2024. PMID: 38497430
Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005.
Wisniewski M, Placide PA, Granier S, Al Shatti Y, Al Qalaf S, Bouattour M, Lamuraglia M, Hammel P. Wisniewski M, et al. Among authors: lamuraglia m. Hepatobiliary Surg Nutr. 2018 Oct;7(5):399-402. doi: 10.21037/hbsn.2018.08.03. Hepatobiliary Surg Nutr. 2018. PMID: 30498718 Free PMC article. No abstract available.
Molecular Landscape of the Coagulome of Oral Squamous Cell Carcinoma.
Lottin M, Soudet S, Fercot J, Racine F, Demagny J, Bettoni J, Chatelain D, Sevestre MA, Mammeri Y, Lamuraglia M, Galmiche A, Saidak Z. Lottin M, et al. Among authors: lamuraglia m. Cancers (Basel). 2022 Jan 17;14(2):460. doi: 10.3390/cancers14020460. Cancers (Basel). 2022. PMID: 35053621 Free PMC article.
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Among authors: lamuraglia m. Nat Commun. 2024 Jun 4;15(1):4753. doi: 10.1038/s41467-024-48915-9. Nat Commun. 2024. PMID: 38834579 Free PMC article. No abstract available.
45 results